Inhibikase Therapeutics (IKT) Equity Average (2020 - 2025)
Historic Equity Average for Inhibikase Therapeutics (IKT) over the last 6 years, with Q3 2025 value amounting to $76.5 million.
- Inhibikase Therapeutics' Equity Average rose 324976.0% to $76.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $76.5 million, marking a year-over-year increase of 324976.0%. This contributed to the annual value of $52.9 million for FY2024, which is 23062.55% up from last year.
- Per Inhibikase Therapeutics' latest filing, its Equity Average stood at $76.5 million for Q3 2025, which was up 324976.0% from $82.9 million recorded in Q2 2025.
- In the past 5 years, Inhibikase Therapeutics' Equity Average ranged from a high of $90.3 million in Q1 2025 and a low of $2.3 million during Q3 2024
- For the 5-year period, Inhibikase Therapeutics' Equity Average averaged around $33.2 million, with its median value being $27.3 million (2022).
- In the last 5 years, Inhibikase Therapeutics' Equity Average plummeted by 8675.82% in 2024 and then skyrocketed by 324976.0% in 2025.
- Over the past 5 years, Inhibikase Therapeutics' Equity Average (Quarter) stood at $40.8 million in 2021, then plummeted by 43.4% to $23.1 million in 2022, then crashed by 43.7% to $13.0 million in 2023, then skyrocketed by 262.89% to $47.2 million in 2024, then skyrocketed by 62.14% to $76.5 million in 2025.
- Its Equity Average stands at $76.5 million for Q3 2025, versus $82.9 million for Q2 2025 and $90.3 million for Q1 2025.